{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T18:48:00Z","timestamp":1788029280941,"version":"build-2784847793"},"reference-count":70,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Emerging Drugs"],"published-print":{"date-parts":[[2021,7,3]]},"DOI":"10.1080\/14728214.2021.1962285","type":"journal-article","created":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T17:57:39Z","timestamp":1627495059000},"page":"295-302","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":19,"title":["Emerging therapeutics in Huntington\u2019s disease"],"prefix":"10.1080","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1717-2568","authenticated-orcid":false,"given":"Robert","family":"Wiggins","sequence":"first","affiliation":[{"name":"NYU Langone\u2019s Fresco Institute for Parkinson\u2019s & Movement Disorders, Department of Neurology, United States of America"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Feigin","sequence":"additional","affiliation":[{"name":"NYU Langone\u2019s Fresco Institute for Parkinson\u2019s & Movement Disorders, Department of Neurology, United States of America"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,8,6]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60111-1"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-36975-0_7"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1159\/000443738"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.5334\/tohm.536"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a024240"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-381328-2.00014-6"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80623-6"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21062146"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2200-5"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2012.05.009"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900907"},{"key":"cit0012","unstructured":"Roche provides update on tominersen programme in manifest Huntington\u2019s disease [Internet]. 2021; [cited 2021 Mar 22]. Available from: https:\/\/www.roche.com\/media\/releases\/med-cor-2021-03-22b.htm"},{"key":"cit0013","unstructured":"Promising drug for Huntington disease fails in major trial [Internet]. Science; 2021; [cited 2021 Mar 23]. Available from: https:\/\/www.sciencemag.org\/news\/2021\/03\/promising-drug-huntington-disease-fails-major-trial"},{"key":"cit0014","unstructured":"Wave Life Sciences Highlights Pipeline Progress and Expansion Leveraging New PN Backbone Chemistry Modifications [Internet]. Wave Life Sciences; 2021; January 11, 2021"},{"key":"cit0015","unstructured":"Wave Life Sciences Announces Topline Data and Addition of Higher Dose Cohort in Ongoing Phase 1b\/2a PRECISION-HD2 Trial in Huntington\u2019s Disease [Internet]. Wave Life Sciences; 2019; December 30, 2019"},{"key":"cit0016","unstructured":"Wave Life Sciences Provides Update on Phase 1b\/2a PRECISION-HD Trials [Internet]. 2021; [cited 2021 Mar 29]. Available from: https:\/\/ir.wavelifesciences.com\/news-releases\/news-release-details\/wave-life-sciences-provides-update-phase-1b2a-precision-hd"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0171127"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.00082"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1038\/nrn3758"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3514"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1016\/j.sbi.2009.12.001"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2015.23"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2018.0762"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1166\/jbn.2014.1929"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1186\/1753-6561-7-S2-K21"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-018-0338-8"},{"key":"cit0027","unstructured":"Voyager Therapeutics Provides Regulatory Update On VY-HTT01 Program [Internet]. 2020; [cited 2020 Oct 12]. Available from: https:\/\/ir.voyagertherapeutics.com\/news-releases\/news-release-details\/voyager-therapeutics-provides-regulatory-update-vy-htt01-program"},{"key":"cit0028","unstructured":"Huntington\u2019s Disease 2018. [updated; cited 2018 Sep 21]. Available from: https:\/\/sparktx.com\/pipelines\/huntingtons-disease\/"},{"key":"cit0029","unstructured":"Novartis receives US Food and Drug Administration (FDA) Orphan Drug Designation for branaplam (LMI070) in Huntington\u2019s disease (HD) [Internet]. 2020; [updated 2020 Oct 21; cited 2021 Feb 21]. Available from: https:\/\/www.novartis.com\/news\/media-releases\/novartis-receives-us-food-and-drug-administration-fda-orphan-drug-designation-branaplam-lmi070-huntington%27s-disease-hd"},{"key":"cit0030","unstructured":"Novartis Releases Update on LMI070 (Branaplam) Clinical Trial [Internet]. 2017; [cited 2017 Sep 19]. Available from: https:\/\/www.curesma.org\/novartis-releases-update-on-lmi070-branaplam-clinical-trial\/"},{"key":"#cr-split#-cit0031.1","unstructured":"PTC Therapeutics Announces that PTC518 Has Entered into a Phase 1 Clinical Trial for the Huntington's Disease Program [Internet]. 2020"},{"key":"#cr-split#-cit0031.2","unstructured":"[cited 2020 Nov 17]. Available from: https:\/\/www.prnewswire.com\/news-releases\/ptc-therapeutics-announces-that-ptc518-has-entered-into-a-phase-1-clinical-trial-for-the-huntingtons-disease-program-301174225.html"},{"key":"cit0032","unstructured":"Therapeutics S Skyhawk Therapeutics Announces Strategic Collaboration with Celgene to Discover and Develop Novel mRNA Splicing Modifiers using Skyhawk\u2019s STAR* Technology Platform. 2018 June 26, 2018"},{"key":"cit0033","unstructured":"Therapeutics T Approach Triplet Therapeutics [cited 2021 Feb 21]. Available from: https:\/\/www.triplettx.com\/approach\/"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)30350-7"},{"key":"cit0035","unstructured":"Triplet Therapeutics Completes Enrollment of SHIELD HD Natural History Study of Huntington\u2019s Disease [Internet]. 2020; [cited 2020 Nov 12]. Available from: https:\/\/www.businesswire.com\/news\/home\/20201112005275\/en\/Triplet-Therapeutics-Completes-Enrollment-of-SHIELD-HD-Natural-History-Study-of-Huntington%E2%80%99s-Disease"},{"key":"cit0036","unstructured":"Triplet Therapeutics Selects Clinical Candidate for Novel Treatment of Repeat Expansion Disorders [Internet]. 2020; [cited 2020 Jul 21]. Available from: https:\/\/www.businesswire.com\/news\/home\/20200721005209\/en\/Triplet-Therapeutics-Selects-Clinical-Candidate-for-Novel-Treatment-of-Repeat-Expansion-Disorders"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0902420106"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1206506109"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0478-3"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.3727\/096368916X690863"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2018.00075"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1172\/JCI92087"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.1670"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1948"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3486"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1038\/nature16526"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2004832117"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.10.025"},{"issue":"215","key":"cit0049","doi-asserted-by":"crossref","first-page":"re1","DOI":"10.1126\/stke.2152004re1","volume":"2004","author":"Rizzuto R","year":"2004","journal-title":"Sci STKE"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.08.036"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0409402102"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(03)00366-0"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1126\/science.2147780"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchemneu.2004.02.005"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddl013"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2015.01.002"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000367"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25964"},{"issue":"7","key":"cit0059","first-page":"28","volume":"4","author":"Busner J","year":"2007","journal-title":"Psychiatry (Edgmont)"},{"key":"cit0060","unstructured":"Vaccinex, Inc. Announces preliminary data from the SIGNAL clinical trial (Investigational Drug VX15\/2503 as a potential treatment for Huntington\u2019s Disease) [Internet]. 2017; [updated April 24, 2017; cited 2021 Feb 28]. Available from: http:\/\/www.globenewswire.com\/news-release\/2017\/04\/24\/970347\/0\/en\/Vaccinex-Inc-Announces-Preliminary-Data-from-the-SIGNAL-Clinical-Trial-Investigational-Drug-VX15-2503-as-a-Potential-Treatment-for-Huntington-s-Disease.html"},{"key":"cit0061","unstructured":"Evans E, editor Results of Phase 2 Huntington\u2019s Disease Trial of Anti-Semaphorin 4D Antibody Pepinemab (SIGNAL) Will Guide Clinical Trial in Alzheimer\u2019s Disease. AD\/PD 2021; [cited 2021 Mar 9]. Virtual."},{"key":"cit0062","unstructured":"Prilenia Enrolls First Patients into its PROOF-HD Phase 3 Clinical Trial for Huntington\u2019s Disease in the United States [Internet]. 2020; [cited 2020 Oct 27]. Available from: https:\/\/www.prilenia.com\/first-proof-hd-patients"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-05030-3"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25362"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70233-2"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.3233\/JHD-170267"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30391-0"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.3233\/JHD-200440"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.3233\/JHD-190393"}],"container-title":["Expert Opinion on Emerging Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14728214.2021.1962285","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T19:37:47Z","timestamp":1672947467000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14728214.2021.1962285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,3]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,7,3]]}},"alternative-id":["10.1080\/14728214.2021.1962285"],"URL":"https:\/\/doi.org\/10.1080\/14728214.2021.1962285","relation":{},"ISSN":["1472-8214","1744-7623"],"issn-type":[{"value":"1472-8214","type":"print"},{"value":"1744-7623","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-05-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}